|Bid||0.00 x 800|
|Ask||0.00 x 900|
|Day's Range||5.76 - 6.09|
|52 Week Range||2.36 - 7.99|
|Beta (5Y Monthly)||1.14|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 15, 2023 - Mar 20, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||19.88|
Subscribe to Yahoo Finance Plus to view Fair Value for ALDX
Insiders who bought Aldeyra Therapeutics, Inc. ( NASDAQ:ALDX ) in the last 12 months may probably not pay attention to...
LEXINGTON, Mass., December 21, 2022--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ADX‑2191 (methotrexate injection, USP), an investigational drug candidate, for the treatment of primary vitreoretinal lymphoma, a rare but potentially fatal cancer with no FDA-approved therapy.
Aldeyra Therapeutics Inc (NASDAQ: ALDX) announced a demonstration of target engagement and improvement in the signs of alcohol intoxication in the Phase 2 trial of ADX-629. Relative to the placebo, ADX-629 reduced dermal flushing, increased Romberg test balance time, and lowered ethanol RASP metabolite acetaldehyde levels following acute alcohol exposure. ADX-629 and placebo were well tolerated, and no safety concerns were noted. Related: Aldeyra's ADX-2191 Aces Late-Stage Study In Rare Vision D